(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 February 2015 (05.02.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/017466 A1

(51) **International Patent Classification**:
A61K 9/00 (2006.01) *A61K 9/28* (2006.01)
A61K 9/16 (2006.01) *A61K 31/5377* (2006.01)
A61K 9/20 (2006.01) *A61P 35/00* (2006.01)

(21) **International Application Number**:
PCT/US2014/048741

(22) **International Filing Date**:
29 July 2014 (29.07.2014)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/860,198 30 July 2013 (30.07.2013) US

(71) **Applicant**: **GILEAD CONNECTICUT, INC.** [US/US]; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(72) **Inventors**: **LI, Bei**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **SPERGER, Diana**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **STEFANIDIS, Dimitrios**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **CASTEEL, Melissa, Jean**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **PAKDAMAN, Rowchanak**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(74) **Agents**: **CHOI, Anita** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2015/017466 A1

(54) **Title**: FORMULATION OF SYK INHIBITORS



(I)

(57) **Abstract**: Disclosed are pharmaceutical compositions comprising a compound having the formula: or a pharmaceutically acceptable salt thereof, or a hydrate of thereof, and at least one pharmaceutically acceptable polymer. The pharmaceutically acceptable salt of the compound of Formula I, or a hydrate thereof, can be a mesylate salt, including, for example, a mono- mesylate or a bis-mesylate salt, or a hydrate thereof. Also disclosed are methods of use for the pharmaceutical composition.